文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

超声引导液体复苏与早期目标导向治疗脓毒性休克患者的系统评价

[Systematic review of ultrasound-guided fluid resuscitation vs. early goal-directed therapy in patients with septic shock].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论系统评价仅纳入2项RCT,超声引导液体复苏较EGDT降低脓毒性休克7天病死率(15.0% vs. 35.0%,P=0.039)并减少24小时静脉补液量(900 mL vs. 1850 mL,P<0.01),但未降低28天病死率、机械通气时间或ICU住院时间。

该系统评价检索万方、CNKI、SinoMed、维普、PubMed、Embase、Cochrane Library和Web of Science至2019年8月,纳入比较超声引导液体复苏与早期目标导向治疗(EGDT)对脓毒性休克患者复苏效果的RCT。最终仅纳入2项英文RCT,超声组分别用下腔静脉塌陷指数(VCCI)和超声评分引导液体复苏,临床异质性大,无法合并,仅做系统评价。一项RCT质量等级B、另一项C,均存在测量偏倚和选择偏倚。结果显示超声组7天病死率15.0% vs. EGDT组35.0%(P=0.039),24小时静脉补液量900 mL vs. 1850 mL(P<0.01),肺水肿发生率15.0% vs. 37.5%(P=0.022);28天病死率、机械通气时间和ICU住院时间两组差异无统计学意义。

要点

  • 超声引导液体复苏较EGDT降低脓毒性休克7天病死率(15.0% vs. 35.0%,P=0.039),但28天病死率无统计学显著差异。
  • 超声组24小时静脉补液量少于EGDT组(900 mL vs. 1850 mL,P<0.01)。
  • 超声组肺水肿发生率低于EGDT组(15.0% vs. 37.5%,P=0.022)。
  • 机械通气时间和ICU住院时间两组差异无统计学意义。
  • 仅2项RCT纳入且无法合并,文献质量等级分别为B和C,结论需谨慎解读。

适用人群与场景

  • 脓毒性休克患者,纳入比较超声引导液体复苏与EGDT复苏效果的RCT研究人群。

处置流程与药物剂量

  • 超声组分别采用下腔静脉塌陷指数(VCCI)和超声评分引导液体复苏,两项RCT方案不同导致临床异质性。
  • 对照组采用早期目标导向治疗(EGDT)进行液体复苏。

研究设计与关键结果

  • 系统评价最终仅纳入2项英文RCT,超声组分别用下腔静脉塌陷指数(VCCI)和超声评分引导液体复苏,临床异质性大,结果无法合并,仅做系统评价。
  • 两项RCT均存在测量偏倚和选择偏倚,文献质量等级分别为B和C。
  • 超声组7天病死率15.0% vs. EGDT组35.0%(P=0.039)。
  • 超声组24小时静脉补液量900 mL vs. EGDT组1850 mL(P<0.01),超声组补液量更少。
  • 超声组肺水肿发生率15.0% vs. EGDT组37.5%(P=0.022),超声组更低。
  • 28天病死率、机械通气时间和ICU住院时间两组差异无统计学意义。

证据类型、等级与局限

  • 证据类型:系统评价,纳入2项RCT。
  • 文献质量等级分别为B和C,两项RCT均存在测量偏倚和选择偏倚。
  • 因临床异质性大,结果无法合并,仅做系统评价而非Meta分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与EGDT相比,超声引导液体复苏对入院7天内的脓毒性休克患者可能有用且实用。
  • 作者认为,超声引导液体复苏不能降低28天病死率、机械通气时间或ICU住院时间。
  • 超声便于评估脓毒性休克患者的反应能力和心脏功能,从而降低肺水肿发生率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To systematically review the efficacy of ultrasound-guided fluid resuscitation and early goal-directed therapy (EGDT) in patients with septic shock.

METHODS: Multiple databases including Wanfang, CNKI, SinoMed, VIP, PubMed, Embase, Cochrane Library and Web of Science were searched from initial to August 2019 for randomized controlled trial (RCT) studies about the comparison of ultrasound-guided fluid resuscitation and EGDT on resuscitation effect in patients with septic shock. Language, country and region were unlimited. Data extraction and quality evaluation were carried out by means of independent review and cross check results by two researchers.

RESULTS: Finally, only two English RCT studies were enrolled. In the two RCT studies, the ultrasound groups used inferior vena cava collapse index (VCCI) and ultrasound score to guide fluid resuscitation, which resulted in clinical heterogeneity. Because the results could not be pooled, only systematic review, not meta-analysis, could be done. There were measurement bias and selection bias in the two RCT studies, and the literature quality level was B and C respectively. System review results showed that using ultrasound would reduce 7-day mortality (15.0% vs. 35.0%, P = 0.039) and prescribe less of 24-hour intravenous fluids (mL: 900 vs. 1 850, P < 0.01) for patients with septic shock as compared with EGDT. Ultrasound was easy to assess the reactive capacity and cardiac function of patients with septic shock, so as to decrease the incidence of pulmonary edema, which was significantly lower than EGDT (15.0% vs. 37.5%, P = 0.022). However, there was no statistically significant difference in 28-day mortality, duration of mechanical ventilation or length of intensive care unit (ICU) stay between the two groups.

CONCLUSIONS: The ultrasound-guided fluid resuscitation may be useful and practical for septic shock patients within 7 days after admission as compared with EGDT, but it cannot reduce the 28-day mortality, duration of mechanical ventilation or length of ICU stay.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yuan J, Yang X, Yuan Q, et al. [Systematic review of ultrasound-guided fluid resuscitation vs. early goal-directed therapy in patients with septic shock]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32148232. doi:10.3760/cma.j.cn121430-20191114-00010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。